Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Tropomyosin receptor kinase (TRK) fusions are oncogenic drivers in various cancers.
• Constitutive TRK activation promotes tumor growth and progression.
• TRK inhibitors are emerging as targeted therapies for TRK fusion-driven cancers.

Purpose of the Study:

• To identify and characterize CH7057288, a novel TRK inhibitor.
• To evaluate the efficacy of CH7057288 against TRK fusion-positive cancers, including resistant mutations.
• To investigate the downstream signaling pathways affected by CH7057288.

Main Methods:

• Cell-free kinase assays to assess inhibitory activity against TRKA, TRKB, and TRKC.
• Cell proliferation assays using TRK fusion-positive and negative cell lines.
• In vivo xenograft and intracranial tumor models to evaluate anti-tumor efficacy.
• Analysis of resistant TRK mutations and X-ray crystallography.
• Gene expression analysis to identify downstream signaling pathways.

Main Results:

• CH7057288 selectively inhibited TRKA, TRKB, and TRKC.
• The compound suppressed proliferation of TRK fusion-positive cell lines and inhibited tumor growth in vivo.
• CH7057288 demonstrated significant tumor regression and improved survival in an intracranial metastasis model.
• The inhibitor maintained activity against a clinically relevant resistant TRK mutation.
• CH7057288 suppressed MAPK and E2F signaling pathways downstream of TRK fusion.

Conclusions:

• CH7057288 is a potent and selective TRK inhibitor with a novel chemical structure.
• It shows significant anti-tumor activity in preclinical models of TRK fusion-positive cancers, including brain metastases.
• CH7057288 is effective against TRK mutations conferring resistance to existing inhibitors.
• The compound warrants further investigation as a potential therapeutic agent for TRK fusion-driven malignancies.